A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma
Michael J. Dennis(University of San Diego), Kathryn A. Gold(University of California San Diego), Assuntina G. Sacco(University of California San Diego), Karen Messer(Human Longevity (United States)), Yuchen Qi(University of California, San Diego), Ruifeng Chen(University of California, San Diego), Ezra E.W. Cohen(Moores Cancer Center), Emily Pittman(University of California, San Diego), Julie Bykowski(University of California, San Diego)
Cited by 21
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
|The Lancet Oncology|2021|618
Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
|Journal of Clinical Oncology|2011|551
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|459